Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Current Deferred Revenue (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Current Deferred Revenue readings, the most recent being $5.4 million for Q1 2017.

  • For the quarter ending Q1 2017, Current Deferred Revenue fell 4.86% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Mar 2017, down 4.86%, and an annual FY2016 reading of $5.1 million, down 4.62% over the prior year.
  • Current Deferred Revenue hit $5.4 million in Q1 2017 for Lisata Therapeutics, up from $5.1 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $7.2 million in Q2 2016, with the low at $362041.0 in Q2 2013.
  • Median Current Deferred Revenue over the past 5 years was $4.6 million (2015), compared with a mean of $4.0 million.
  • The sharpest move saw Current Deferred Revenue plummeted 77.81% in 2013, then surged 681.83% in 2014.
  • Year by year, Current Deferred Revenue stood at $1.8 million in 2013, then skyrocketed by 138.58% to $4.3 million in 2014, then increased by 23.33% to $5.3 million in 2015, then fell by 4.62% to $5.1 million in 2016, then increased by 5.23% to $5.4 million in 2017.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $5.4 million, $5.1 million, and $5.9 million for Q1 2017, Q4 2016, and Q3 2016 respectively.